Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camille Carroll

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
NPJ Parkinson'S Disease|August 31, 2023
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson's diseaseAlejandro Martinez-Carrasco, Raquel Real, Michael Lawton, et al.
Neurology and Therapy|October 4, 2025
Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Post Hoc Analysis of Two Phase 3 Clinical TrialsRajesh Pahwa, Jason Aldred, Michael J Soileau, et al.
Journal of Parkinson'S Disease|January 22, 2024
Real-World Evaluation of the Feasibility, Acceptability and Safety of a Remote, Self-Management Parkinson's Disease Care Pathway: A Healthcare Improvement InitiativeAngie A Kehagia, Sarah Chowienczyk, Michelle Helena van Velthoven, et al.
Neurology and Therapy|August 26, 2023
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyJason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Journal of Parkinson'S Disease|February 20, 2025
Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studiesDavid Devos, Olivier Rascol, Wassilios G Meissner, et al.
Journal of Parkinson'S Disease|April 5, 2024
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials InitiativeRichard K Wyse, Tom Isaacs, Roger A Barker, et al.
Drug Discovery Today|April 18, 2026
Decentralised clinical trials of investigational medicinal productsAbdel Douiri, Mohammad Alhnan, Muhammad Rizwan Asghar, et al.
Journal of Parkinson'S Disease|June 9, 2020
GDNF and Parkinson's Disease: Where Next? A Summary from a Recent WorkshopRoger A Barker, Anders Björklund, Don M Gash, et al.
NPJ Parkinson'S Disease|November 20, 2024
Accelerating Parkinson's Disease drug development with federated learning approachesAmit Khanna, Jamie Adams, Chrystalina Antoniades, et al.
Lancet (London, England)|February 7, 2025
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trialNirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
NPJ Parkinson'S Disease|August 31, 2023
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson's diseaseAlejandro Martinez-Carrasco, Raquel Real, Michael Lawton, et al.
Neurology and Therapy|October 4, 2025
Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Post Hoc Analysis of Two Phase 3 Clinical TrialsRajesh Pahwa, Jason Aldred, Michael J Soileau, et al.
Journal of Parkinson'S Disease|January 22, 2024
Real-World Evaluation of the Feasibility, Acceptability and Safety of a Remote, Self-Management Parkinson's Disease Care Pathway: A Healthcare Improvement InitiativeAngie A Kehagia, Sarah Chowienczyk, Michelle Helena van Velthoven, et al.
Neurology and Therapy|August 26, 2023
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyJason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Journal of Parkinson'S Disease|February 20, 2025
Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studiesDavid Devos, Olivier Rascol, Wassilios G Meissner, et al.
Journal of Parkinson'S Disease|April 5, 2024
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials InitiativeRichard K Wyse, Tom Isaacs, Roger A Barker, et al.
Drug Discovery Today|April 18, 2026
Decentralised clinical trials of investigational medicinal productsAbdel Douiri, Mohammad Alhnan, Muhammad Rizwan Asghar, et al.
Journal of Parkinson'S Disease|June 9, 2020
GDNF and Parkinson's Disease: Where Next? A Summary from a Recent WorkshopRoger A Barker, Anders Björklund, Don M Gash, et al.
NPJ Parkinson'S Disease|November 20, 2024
Accelerating Parkinson's Disease drug development with federated learning approachesAmit Khanna, Jamie Adams, Chrystalina Antoniades, et al.
Lancet (London, England)|February 7, 2025
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trialNirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
Pageof 6